Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III napabucasin plus nab-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma
NL-OMON50631Phase 3Active, not recruiting
- Sponsor
- Sumitomo Pharma Oncology
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of napabucasin in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Sumitomo Pharma Oncology. Primary endpoint: Overall survival. Started Jan 2018; status: active, not recruiting.
02
Drugs
napabucasin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON50631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50631.